Abstract
Chromosome instability (CIN) is one of the most important phenotypes in tumor progression, introducing multiple mutations required for acquisition of further malignant characteristics. Abnormal amplification of centrosomes, which is frequently observed in human cancer, has been shown to contribute to CIN by increasing the frequency of mitotic defects. Here, we show that transient exposure to subtoxic concentrations of commonly used anticancer drugs that target DNA synthesis induces centrosome amplification in cells lacking p53 tumor suppressor protein, by allowing continuous centrosome duplication in the absence of DNA synthesis. When these cells are released from cell cycle arrest by removal of drugs, cells suffer extensive destabilization of chromosomes. Considering that p53 is the most frequently mutated gene in human cancer and that CIN is known to be associated with acquisition of malignant phenotypes, our observations may explain why recurrent tumors, after chemotherapy, often exhibit more malignant characteristics than the original tumors. The tumor cells that are exposed to subtoxic levels of DNA synthesis-targeting drugs will be arrested and undergo centrosome amplification. Upon cessation of chemotherapy, these cells will re-enter cell cycling, and experience extensive CIN due to the presence of amplified centrosomes. This in turn promotes generation of tumor cells equipped with further malignant characteristics.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Balczon R, Bao L, Zimmer WE, Brown K, Zinkowski RP and Brinkley BR . (1995). J. Cell Biol., 130, 105–115.
Brinkley BR and Goepfert TM . (1998). Cell Motil. Cytoskeleton, 41, 281–288.
Carroll PE, Okuda M, Horn HF, Biddinger P, Stambrook PJ, Gleich LL, Li Y-Q, Tarapore P and Fukasawa K . (1999). Oncogene, 18, 1935–1944.
Chen S, Blanck G and Pollack RE . (1983). Proc. Natl. Acad. Sci. USA, 80, 5670–5674.
Cheng KC and Loeb LA . (1993). Adv. Cancer Res., 60, 121–156.
Chiba S, Okuda M, Mussman JG and Fukasawa K . (2000). Exp. Cell Res., 258, 310–321.
D'Assoro AB, Lingle WL and Salisbury JL . (2002). Oncogene, 21, 6146–6153.
Doxsey S . (2001). Nat. Rev. Mol. Cell. Biol., 2, 688–698.
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B . (1993). Cell, 75, 817–825.
Fukasawa K . (2002). Oncogene, 21, 6140–6145.
Fukasawa K, Choi T, Kuriyama R, Rulong S and Vande Woude GF . (1996). Science, 271, 1744–1747.
Gu Y, Turck CW and Morgan DO . (1993). Nature, 366, 707–710.
Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ . (1993). Cell, 75, 805–816.
Harris CC . (1996). J. Natl. Cancer Inst., 88, 1442–1455.
Hinchcliffe EH, Li C, Thompson EA, Maller JL and Sluder G . (1999). Science, 283, 851–854.
Hollstein M, Sidransky D, Vogelstein B and Harris CC . (1991). Science, 253, 49–53.
Izumi H, Hara T, Oga A, Matsuda K, Sato Y, Naito K and Sasaki K . (2002). Neoplasia, 4, 103–111.
Lacey KR, Jackson PK and Stearns T . (1999). Proc. Natl. Acad. Sci. USA, 96, 2817–2822.
Lange BM and Gull K . (1996). Trends Cell Biol., 6, 348–352.
Levine AJ, Momand J and Finlay CA . (1991). Nature, 351, 453–456.
Mazia D . (1987). Int. Rev. Cytol., 100, 49–92.
Meraldi P, Honda R and Nigg EA . (2002). EMBO J., 21, 483–492.
Nayak BK and Das GM . (2002). Oncogene, 21, 7226–7229.
Oakley BR . (1996). Trends Cell Biol., 2, 1–5.
Stearns T, Evans L and Kirschner M . (1991). Cell, 65, 825–836.
Tarapore P and Fukasawa K . (2002). Oncogene, 21, 6234–6240.
Tarapore P, Horn HF, Tokuyama Y and Fukasawa K . (2001). Oncogene, 20, 3173–3184.
Vandre DD and Borisy GG . (1989). Mitosis: Molecules and Mechanisms Hyams JS and Brinkley BR (eds). Academic press, San Diego, 39–75.
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D . (1993). Nature, 366, 701–704.
Acknowledgements
We thank E Hunter and K George for their technical assistance. This research sponsored by National Institute of Health (CA90522) and National Cancer Institute Training Grant (RB).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bennett, R., Izumi, H. & Fukasawa, K. Induction of centrosome amplification and chromosome instability in p53-null cells by transient exposure to subtoxic levels of S-phase-targeting anticancer drugs. Oncogene 23, 6823–6829 (2004). https://doi.org/10.1038/sj.onc.1207561
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207561
Keywords
This article is cited by
-
Centrosome amplification, chromosomal instability and cancer: mechanistic, clinical and therapeutic issues
Chromosome Research (2016)
-
DNA-PK/Chk2 induces centrosome amplification during prolonged replication stress
Oncogene (2015)
-
Chloroquine alleviates etoposide-induced centrosome amplification by inhibiting CDK2 in adrenocortical tumor cells
Oncogenesis (2015)
-
Mustard gas surrogate, 2-chloroethyl ethylsulfide (2-CEES), induces centrosome amplification and aneuploidy in human and mouse cells
Cell Biology and Toxicology (2014)
-
Roles of cyclins A and E in induction of centrosome amplification in p53-compromised cells
Oncogene (2008)